EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study)



Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study)



Journal of Clinical Oncology 23(16_suppl): 3517-3517



NlmCategory="UNASSIGNED">3517 Background: The LIFE study was designed to demonstrate a 10% absolute improvement in survival at 2 years (from 20 to 30%), with the addition of oxaliplatin in first line to the 5-FU followed by irinotecan sequence in advanced colorectal cancer (ACRC). A total of 725 ACRC patients from UK (46%), Poland (39%), other countries (15%), were randomized from March 2001 to March 2002 to receive 5-FU monotherapy (Lockich or de Gramont regimens) or the same regimen plus oxaliplatin 85mg/m2, repeated every 2 weeks. Second line therapy was standardized with irinotecan 350 mg/m2 single agent repeated every 3 weeks, in both arms. Patients'characteristics were well balanced except for metastatic sites (liver + other in 88% versus 76% of patients receiving oxaliplatin/5FU or 5FU respectively). Safety results are in line with the safety profiles of the drugs, without any unexpected toxicities (Cassidy, ASCO 2003). Median number of cycles (10) was the same in both arms, with a higher dose of 5-FU in the control arm. Median cumulative dose of oxaliplatin was 845 mg/m2. Relative oxaliplatin dose intensity was 87%. Direct efficacy evaluation of the first line treatment showed improvement in response rate -RR- (54% versus 30%, p< 0.0001) and progression free survival -PFS- (7.9 versus 5.9 months, p <0.0001) in the oxaliplatin arm in accordance with previously reported trials. This did not translate into overall survival advantage (15.9 versus 15.2 months) with a median in the oxaliplatin arm below the 19-20 months obtained in more recent studies. These results confirm the improvement in RR and PFS observed with combination therapy in first line ACRC. Overall survival results could be explained by the low number of patients receiving second line irinotecan therapy in the oxaliplatin arm (41%) and thus exposed to the 3 active agents: 5-FU, oxaliplatin and irinotecan. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 057877410

Download citation: RISBibTeXText

PMID: 27944393



Related references

A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Annals of Oncology 18(12): 2000-2005, 2007

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Annals of Oncology 16(6): 869-877, 2005

Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. Journal of Clinical Oncology 23(16_suppl): 3618-3618, 2016

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Annals of Oncology 21(4): 781-786, 2010

Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA Study. Journal of Clinical Oncology 23(16_suppl): 3617-3617, 2016

Capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer Updated results of a randomized phase II Trial. EJC Supplements 1(5): S90-S91, September, 2003

Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anti-Cancer Drugs 11(8): 629-634, 2000

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncologica 47(2): 286-292, 2007

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of Oncology 24(6): 1580-1587, 2013

A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC). Journal of Clinical Oncology 24(18_suppl): 13540-13540, 2016

Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). Journal of Clinical Oncology 26(15_suppl): 4030-4030, 2016

Results of 3 rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Journal of Clinical Oncology 23(16_suppl): 3519-3519, 2016

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Design, Development and Therapy 9(): 3099-3108, 2016

Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 20(1): 165-172, 2002

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clinical & Translational Oncology 14(8): 606-612, 2013